Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways

Src activation is involved in cancer progression and the interplay with EGFR. Inhibition of Src activity also represses the signalling pathways regulated by EGFR. Therefore, Src has been considered a target molecule for drug development. This study aimed to identify the compounds that target Src to...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Yi-Hua, Chen, Min-Hsuan, Lin, Sih-Yin, Lin, Sheng-Yi, Wong, Yung-Hao, Yu, Sung-Liang, Chen, Huei-Wen, Yang, Chih-Hsin, Chang, Gee-Chen, Chen, Jeremy J.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694899/
https://www.ncbi.nlm.nih.gov/pubmed/26312766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694899/
https://www.ncbi.nlm.nih.gov/pubmed/26312766

Ejemplares similares